Sustainability Phase: Inhaled Corticosteroids for All Asthma During COVID-19 Pandemic
Care Process & Redesign
National Healthcare Group Quality Improvement
National Healthcare Group
31 December 2022
To sustain prescription of inhaled corticosteroids (ICS) in asthma patients above 92% following clinical improvements. Regular ICS prescriptions for asthma patients reduce exacerbations, improving patient outcomes and healthcare efficiency.
Year Submitted: 2022
Published Date: 31 December 2022
Tags: Care Process ＆ Redesign, Productivity, Cost Saving, Quality Improvement, Clinical Practice Improvement
About this Content
Aims
To sustain prescription of inhaled corticosteroids (ICS) in asthma patients above 92% following clinical improvements.
Background
Asthma management shifted focus to ICS over SABA-only treatments per updated guidelines.
Methods
Regular feedback, education, and asthma nurse reviews.
Results
Sustained ICS prescriptions post-intervention, with cost savings and improved patient outcomes.
Conclusion
Regular ICS prescriptions for asthma patients reduce exacerbations, improving patient outcomes and healthcare efficiency.
Lessons Learnt
Knowledge updates and communication improve adoption of evidence-based treatments.
Additional Information
NHG Quality Day 2022: Sustained Safety Initiative Award
Keywords
Inhaled Corticosteroids, Asthma, Clinical Guidelines
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | National Healthcare Group |
Organization(s) Involved | Tan Tock Seng Hospital |
Platform(s) | National Healthcare Group Quality Improvement |
Healthcare Professional Group(s) | Nursing, Medical, Pharmacy |
Applicable Specialty or Discipline | Respiratory Therapy, Intensive Care Medicine, Emergency Medicine |
Project Lead(s) | Esther Pang Pee Hwee |
Project Member(s) | T Lee |
Connect with this contributor!
Dr Esther Pang Pee Hwee - pee_hwee_pang@ttsh.com.sg
Project Attachment
C_512_TTSH_Quality_Day_2022_Sustainability_Phase_Inhaled_Corticosteroids.pdf